Poseida Therapeutics, Inc. (PSTX) Tops Q2 EPS by 21c
Tweet
Share
E-mailGet Alerts PSTX Hot Sheet
Join SI Premium – FREE
Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q2 EPS of ($0.32), $0.21 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $20.01 million versus the consensus estimate of $11.96 million.
For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Stardust Power (SDST) Tops Q2 EPS by 1c
- RCM Technologies (RCMT) Tops Q2 EPS by 17c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
